Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe this is a good deal for Jazz.

A study by Mass General Brigham found that taking the weight-loss drug semaglutide before bariatric surgery does not lead to ...

These diabetes drugs for weight loss include: GLP-1 receptor Agonists . Glucagon-like peptide-1 receptor agonists (mercifully abbreviated to GLP-1 RAs) are a class of medications that stimulate ...

General and administrative (G&A) expenses for the fourth quarter of 2024 were $24.1 million, compared to $14.2 million for the fourth quarter of 2023. G&A expenses for the full year 2024 were $77.1 ...

Shaw and Andrew Aguirre, an oncologist and pancreatic cancer researcher, are co-leading the newly launched Center for RAS Therapeutics, coordinating the prosecution of drugs aimed at KRAS ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...